Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical mupirocin prophylaxis for indwelling pleural catheter infection prevention in malignant pleural effusion
ACTRN12623000253606Phase 2Active, not recruiting
- Sponsor
- Institute for Respiratory Health
- Start
- Jul 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of mupirocin in malignant pleural effusion (MPE) (2 arms), sponsored by Institute for Respiratory Health. Primary endpoint: Percentage of patients developing IPC-related infection. Started Jul 2023; status: active, not recruiting.
02
Drugs
mupirocin
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on ACTRN12623000253606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000253606.